RU94040869A - PHARMACEUTICAL COMPOSITIONS CONTAINING RANITIDINE SALTS AND BISMUTH CARBOXYLATES AND THE METHOD FOR PRODUCING THEM - Google Patents

PHARMACEUTICAL COMPOSITIONS CONTAINING RANITIDINE SALTS AND BISMUTH CARBOXYLATES AND THE METHOD FOR PRODUCING THEM

Info

Publication number
RU94040869A
RU94040869A RU94040869/14A RU94040869A RU94040869A RU 94040869 A RU94040869 A RU 94040869A RU 94040869/14 A RU94040869/14 A RU 94040869/14A RU 94040869 A RU94040869 A RU 94040869A RU 94040869 A RU94040869 A RU 94040869A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
composition according
methyl
bismuth
ranitidine
Prior art date
Application number
RU94040869/14A
Other languages
Russian (ru)
Other versions
RU2108097C1 (en
Inventor
Джон Дуглас Стефен
Рой Хеппенстол Колин
Ричард Смит Норман
Original Assignee
Глэксо Груп Лимитед
Filing date
Publication date
Priority claimed from GB909019875A external-priority patent/GB9019875D0/en
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of RU94040869A publication Critical patent/RU94040869A/en
Application granted granted Critical
Publication of RU2108097C1 publication Critical patent/RU2108097C1/en

Links

Claims (13)

1. Фармацевтическая композиция в твердой единичной дозированной форме, пригодная для орального ввода в организм, включающая эффективное количество соли, образуемой ранитидином и комплексом висмута с карбоновой кислотой, выбранной из группы тартаровой кислоты и лимонной кислоты, вместе с щелочной солью.1. The pharmaceutical composition in solid unit dosage form suitable for oral administration into the body, comprising an effective amount of the salt formed by ranitidine and a complex of bismuth with a carboxylic acid selected from the group of tartaric acid and citric acid, together with an alkaline salt. 2. Фармацевтическая композиция по п.1, содержащая от 200 до 800 мг ранитидина-висмута-карбоксилата на единичную дозу. 2. The pharmaceutical composition according to claim 1, containing from 200 to 800 mg of ranitidine-bismuth-carboxylate per unit dose. 3. Фармацевтическая композиция по п. 1 или 2, содержащая от 2 до 20 мас. % щелочной соли. 3. The pharmaceutical composition according to claim 1 or 2, containing from 2 to 20 wt. % alkaline salt. 4. Фармацевтическая композиция по п. 1 или 2, содержащая от 2 до 8 мас.% щелочной соли. 4. The pharmaceutical composition according to claim 1 or 2, containing from 2 to 8 wt.% Alkaline salt. 5. Фармацевтическая композиция по любому из пп.1 - 4, содержащая от 50 до 95 мас.% ранитидина-висмута-карбоксилата. 5. The pharmaceutical composition according to any one of claims 1 to 4, containing from 50 to 95 wt.% Ranitidine-bismuth-carboxylate. 6. Фармацевтическая композиция по любому из пп.1 - 5, отличающаяся тем, что соль ранитидина представляет собой комплекс N-[2-[[[5-[(диметиламино)метил] -2-фуранил] метил] -тио] этил]-N,-метил-2-нитро-1,1-этендиамин-2 -окси-1,2,3-пропантрикарбоксилат-висмут (3+) или комплекс N-[2-[[[5-[(диметиламино)метил] -2-фуранил]метил]тио]этил]-N,- метил-2-нитро-1,1-этандиамин [R-(R*R*)]2,3-диоксибутандиоат-висмут (3+).6. The pharmaceutical composition according to any one of claims 1 to 5, characterized in that the ranitidine salt is a complex of N- [2 - [[[5 - [(dimethylamino) methyl] -2-furanyl] methyl] -thio] ethyl] -N , -methyl-2-nitro-1,1-ethendiamine-2 -oxy-1,2,3-propanetricarboxylate-bismuth (3+) or the complex N- [2 - [[[5 - [(dimethylamino) methyl ] -2-furanyl] methyl] thio] ethyl] -N , - methyl-2-nitro-1,1-ethanediamine [R- (R * R * )] 2,3-dioxibutanedioate-bismuth (3+). 7. Фармацевтическая композиция по любому из пп.1 - 6, отличающаяся тем, что соль щелочного металла представляет собой карбонат, бикарбонат, цитрат, фосфат или ацетат. 7. The pharmaceutical composition according to any one of claims 1 to 6, characterized in that the alkali metal salt is a carbonate, bicarbonate, citrate, phosphate or acetate. 8. Фармацевтическая композиция по любому из пп. 1 - 6, отличающаяся тем, что щелочная соль представляет собой карбонат или бикарбонат щелочного или щелочноземельного металла или их смесь. 8. The pharmaceutical composition according to any one of paragraphs. 1 to 6, characterized in that the alkaline salt is a carbonate or bicarbonate of an alkali or alkaline earth metal, or a mixture thereof. 9. Фармацевтическая композиция по любому из пп.1 - 6, отличающаяся тем, что щелочная соль представляет собой карбонат натрия и/или бикарбонат натрия. 9. The pharmaceutical composition according to any one of claims 1 to 6, characterized in that the alkaline salt is sodium carbonate and / or sodium bicarbonate. 10. Фармацевтическая композиция по любому из пп.1 - 5, отличающаяся тем, что ранитидин-висмут-карбоксилат представляет собой комплекс N-[2-[[[5-[(диметиламино)метил] -2-фуранил] метил]тио]этил]-N,-метил-2-нитро-1, 1-этендиамин-2-окси-1,2,3-пропантрикарбоксилат-висмут (3+) и щелочная соль представляет собой карбонат натрия.10. The pharmaceutical composition according to any one of claims 1 to 5, characterized in that ranitidine-bismuth-carboxylate is a complex of N- [2 - [[[5 - [(dimethylamino) methyl] -2-furanyl] methyl] thio] ethyl] -N , methyl-2-nitro-1, 1-ethenediamine-2-hydroxy-1,2,3-propanetricarboxylate-bismuth (3+) and the alkaline salt is sodium carbonate. 11. Фармацевтическая композиция по любому из пп. 1-10, имеющая форму таблеток. 11. The pharmaceutical composition according to any one of paragraphs. 1-10, in the form of tablets. 12. Фармацевтическая композиция по любому из пп.1 - 10, содержащая также один или несколько физиологически пригодных носителей или эксцепиентов. 12. The pharmaceutical composition according to any one of claims 1 to 10, also containing one or more physiologically suitable carriers or excipients. 13. Способ получения фармацевтической композиции по любому из пп.1 - 12, отличающийся тем, что включает обработку ранитидина-висмута-карбоксилата и щелочной соли с превращением их в твердую единичную дозированную форму, пригодную для орального ввода в организм. 13. A method of obtaining a pharmaceutical composition according to any one of claims 1 to 12, characterized in that it includes the treatment of ranitidine-bismuth-carboxylate and alkaline salt with their transformation into a solid unit dosage form suitable for oral administration to the body.
RU94040869A 1990-09-11 1992-03-05 Pharmaceutical composition containing ranitidin and bismuth carboxylate salt and method for its preparation RU2108097C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909019875A GB9019875D0 (en) 1990-09-11 1990-09-11 Pharmaceutical compositions
NO920408A NO179694C (en) 1990-09-11 1992-01-30 Pharmaceutical preparations containing ranitidine derivatives
PCT/EP1992/000498 WO1993017679A1 (en) 1990-09-11 1992-03-05 Compositions containing ranitidine/bismuth carboxylates salts

Publications (2)

Publication Number Publication Date
RU94040869A true RU94040869A (en) 1997-11-10
RU2108097C1 RU2108097C1 (en) 1998-04-10

Family

ID=47884627

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94040869A RU2108097C1 (en) 1990-09-11 1992-03-05 Pharmaceutical composition containing ranitidin and bismuth carboxylate salt and method for its preparation

Country Status (33)

Country Link
US (1) US5456925A (en)
EP (1) EP0558779B1 (en)
JP (1) JPH0692849A (en)
KR (1) KR100196308B1 (en)
AT (2) AT405134B (en)
AU (2) AU640816B2 (en)
BE (1) BE1005115A5 (en)
BG (1) BG61931B1 (en)
CA (1) CA2050970C (en)
CH (1) CH683068A5 (en)
CY (1) CY1988A (en)
DE (2) DE4130061A1 (en)
DK (1) DK159191A (en)
ES (1) ES2072647T3 (en)
FI (1) FI944047A (en)
FR (1) FR2666508B1 (en)
GB (2) GB9019875D0 (en)
HK (1) HK60894A (en)
HU (1) HU211846A9 (en)
IE (1) IE65049B1 (en)
IL (1) IL99428A (en)
IT (1) IT1249696B (en)
MX (1) MX9101009A (en)
NL (1) NL194907C (en)
NO (1) NO179694C (en)
NZ (1) NZ239731A (en)
OA (1) OA10093A (en)
RO (1) RO112084B1 (en)
RU (1) RU2108097C1 (en)
SE (1) SE509694C2 (en)
SK (1) SK279591B6 (en)
WO (1) WO1993017679A1 (en)
ZA (1) ZA917176B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
DE69228738D1 (en) * 1991-12-06 1999-04-29 Glaxo Group Ltd Inflammatory or analgesic compositions containing ranitidine bismuth citrate and an NSAID
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
GB9501560D0 (en) 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
US6117412A (en) * 1995-01-26 2000-09-12 Nycomed Imaging As Non-cluster type bismuth compounds
WO2000010562A1 (en) * 1998-08-18 2000-03-02 Leonidov Nikolai B Physically stable and x-ray amorphous form of hydrochloride ranitidine having an increased anti-ulcer activity and method for producing the same
EP1104673A1 (en) * 1999-11-30 2001-06-06 Bayer Classics A hydrogen carbonate-containing, desintegrating agent-free pharmaceutical composition
KR100412290B1 (en) * 2001-11-27 2003-12-31 주식회사 동구제약 Composition of suspension containing ranitidine and its manufacturing process
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
US9629809B2 (en) 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
WO2010011522A1 (en) * 2008-07-21 2010-01-28 Albemarle Corporation High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
CN115697354A (en) * 2020-06-01 2023-02-03 香港大学 Compositions and methods for treating SARS-COV-2 infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608257A (en) * 1984-01-03 1986-08-26 Board Of Regents For Oklahoma State University Composition and method for treating heat stress
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
EP0282132B1 (en) * 1987-03-09 1992-09-30 The Procter & Gamble Company Compositions and their use for treating gastrointestinal disorders
DE3710462A1 (en) * 1987-03-30 1988-10-13 Heumann Pharma Gmbh & Co PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF DISEASES OF THE gastrointestinal tract
FR2633181B1 (en) * 1988-06-24 1992-01-10 Glaxo Lab Sa RANITIDINE-BASED PHARMACEUTICAL COMPOSITION AND PROCESS FOR PREPARING THE SAME
CH679582A5 (en) * 1988-07-18 1992-03-13 Glaxo Group Ltd
ES2040307T3 (en) * 1988-10-08 1993-10-16 Dr. R. Pfleger Chemische Fabrik Gmbh PROCEDURE FOR PRODUCING A LIQUID MEDICINAL PREPARATION CONTAINING BISMUTE.
AU641903B2 (en) * 1988-10-26 1993-10-07 Glaxo Group Limited Carboxylic acid derivatives
US5013560A (en) * 1989-03-17 1991-05-07 The Procter & Gamble Company Microbially-stable bismuth-containing liquid pharmaceutical suspensions
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions

Similar Documents

Publication Publication Date Title
AU627194B2 (en) Pharmaceutical compositions
RU94040869A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING RANITIDINE SALTS AND BISMUTH CARBOXYLATES AND THE METHOD FOR PRODUCING THEM
KR910002826A (en) Furan derivatives
RU2003100507A (en) PHARMACEUTICAL COMPOSITIONS
KR920005984A (en) Pharmaceutical Compositions Containing Furan Derivatives
KR100263284B1 (en) More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent
US3829561A (en) Iron preparation and process for its manufacture
RU96119364A (en) DERIVATIVE BENZAMIDE, COMPOSITIONS CONTAINING SUPERIOR DERIVATIVE, AND THEIR APPLICATION
US5728401A (en) Effervescent ranitidine formulations
US3621094A (en) Concentrated aqueous liquid antacid compositions containing certain phosphate and gluconate salts
US4190655A (en) Amiloride citrate
RU2001126056A (en) The use of (R) -arylpropionic acids for the manufacture of medicaments for the treatment of diseases of humans and animals that can be treated with therapeutic effect by inhibiting the activation of NF-kB
DE3517820A1 (en) PHARMACEUTICAL PREPARATIONS WITH ANTI-HYPERTENSIVE AND CARDIOPROTECTIVE EFFECT
CA2171829A1 (en) Oral water soluble pharmaceutical compositions containing estrone derivative and calcium salt
EP2528593A2 (en) Effervescent formulations comprising cefprozil as active agent
RU98101105A (en) NEW APPLICATION FOR MEDICAL PURPOSES
RU99100703A (en) MODIFIED FORM OF HYDROCHLORIDE R (-) - N - (4,4-DI (3-METHYL-THIEN-2-IL) BUT-3-ENYL) -NIPECOTHIC ACID
US3852454A (en) Treatment of rheumatoid arthritis
US4391809A (en) Methods for treating psoriasis
JP2007077116A (en) Organ fiberization inhibitor
JPS57144214A (en) Pharmaceutical preparation for rectum medication
JPH0539226A (en) Medicine for cytomegalovirus infectious disease
UA27002C2 (en) Pharmaceutical composition in solid unit dosage form adapted for oral administration for treatment of gastrointestinal tract upset comprising ranitidine salt and a bismuth carboxylate and method for its preparation
CZ281514B6 (en) Pharmaceutical preparation
JPS647967B2 (en)